ProQR Therapeutics
543 Bryant Street
Palo Alto
California
94301
United States
Website: https://proqr-tx.com/
Email: info@proqr-tx.com
About ProQR Therapeutics
We are ProQR, a biotechnology company dedicated to changing lives by developing RNA therapies for rare genetic diseases. We focus our drug development mainly on a group of blinding disorders affecting the retina, called inherited retinal diseases.
110 articles with ProQR Therapeutics
-
ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022
5/9/2022
ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced a presentation at the Oligonucleotide and Peptide Therapeutics conference, or TIDES USA, that is being held May 9-12, 2022 in Boston, MA, U.S.
-
ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022
4/26/2022
ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced several presentations at the 7th Annual Retinal Cell and Gene Therapy Innovation Summit being held Friday, April 29, 2022 and the Annual Meeting.
-
ProQR to Participate in the Kempen Life Sciences Conference
4/19/2022
ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies, announced that Company management will participate in the Kempen Life Sciences Conference on April 20, 2022.
-
ProQR Therapeutics, which is developing RNA therapies for genetic eye diseases, announced Wednesday that it will be restructuring and laying off 30% of its staff.
-
ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy
4/13/2022
ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today provided an update on its sepofarsen program, following a comprehensive post-hoc analysis of the data from the Phase 2/3 Illuminate trial in people with CEP290-mediated Leber congenital amaurosis 10, or LCA10, a severe inherited retinal disease.
-
ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit
4/4/2022
ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, announced a presentation at the 3rd RNA Editing Summit held April 5-7 in Boston, MA, US.
-
ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit - Mar 23, 2022
3/23/2022
ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, announced that Company management will participate in the Cantor Virtual Rare Orphan Disease Summit on March 29 as part of the RNA Therapeutics in Rare Diseases panel from 2:45-3:45pm EDT.
-
Foundation Fighting Blindness and InformedDNA Partner to Engage and Screen Patients for ProQR's Pivotal Usher Syndrome and Retinitis Pigmentosa Clinical Trials
3/8/2022
The Foundation Fighting Blindness is partnering with ProQR Therapeutics and InformedDNA® to accelerate patient identification and enrollment in clinical research for people with Usher syndrome or non-syndromic retinitis pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.
-
ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board
3/7/2022
ProQR Therapeutics N.V. today announced that John Maraganore, PhD, biopharma industry leader and the former founding CEO of Alnylam Pharmaceuticals, has joined ProQR as a strategic advisor.
-
ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results
2/24/2022
ProQR Therapeutics N.V. reported its financial and operating results for the fourth quarter and full year ended December 31, 2021, and provided a business update.
-
ProQR Therapeutics has reported that their drug sepofarsen failed to meet its primary and secondary endpoints in recent Phase II/III clinical trials.
-
ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10
2/11/2022
ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced its pivotal Phase 2/3 Illuminate trial of sepofarsen for the treatment of CEP290-mediated Leber congenital amaurosis 10 (LCA10) did not meet its primary endpoint of Best Corrected Visual Acuity (BCVA) at Month 12.
-
ProQR to Present at Upcoming SVB Leerink Conference
2/7/2022
ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, announced that Company management will present at the upcoming virtual SVB Leerink 11th Annual Global Healthcare Conference.
-
Various pharmaceutical companies announced collaborations and licensing agreements from January 31 to February 1.
-
Clinical Catch-Up: January 3-7
1/10/2022
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look. -
Biopharma and life sciences companies and organizations provide updates on their businesses and pipelines.
-
ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen
1/4/2022
ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases today announced that the last patient completed their last visit (Month 12) in the Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated Leber Congenital Amaurosis 10 (LCA10) due to the p.Cys998X mutation, also known as c.2991+1655A>G.
-
ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital
12/30/2021
ProQR Therapeutics N.V. today announced that it has amended its convertible debt financing agreement entered into in 2020 with Kreos Capital (“Kreos”) and Pontifax Medison Debt Financing (“Pontifax”).
-
ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa
12/16/2021
ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the first patients dosed in Phase 2/3 Sirius and Celeste clinical trials of investigational RNA therapy QR-421a for people with USH2A mediated retinitis pigmentosa (RP) and Usher syndrome.
-
ProQR to Webcast Virtual Analyst Event on November 18, 2021
11/11/2021
ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, will webcast a virtual Analyst Event on November 18, 2021, from 12-2pm ET to highlight its clinical stage pipeline programs and the Axiomer® RNA editing platform.